Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis

Journal of Neuroinflammation

Volumn 11, Issue 1, 2014, Pages

  Selenica, Maj Linda B ^a,b   Davtyan, Hayk ^c,d   Housley, Steven B ^b,e   Blair, Laura J ^b,e   Gillies, Anne ^f   Nordhues, Bryce A ^b,e   Zhang, Bo ^b,e   Liu, Joseph ^a,b   Gestwicki, Jason E ^f   Lee, Daniel C ^a,b   Gordon, Marcia N ^b,e   Morgan, Dave ^b,e   Dickey, Chad A ^b,e  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c INSTITUTE FOR MOLECULAR MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Active immunization; Immunogenicity; Neuroinflammation; Peripheral response; Tau

Indexed keywords

EPITOPE; QUIL A; RECOMBINANT PROTEIN; TAU PROTEIN; ANTIBODY; CYTOKINE; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOLOGICAL ADJUVANT; SAPONIN;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BRAIN HISTOLOGY; CARBOXY TERMINAL SEQUENCE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOTHERAPY; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PATHOGENESIS; PROLINE RICH PROTEIN DOMAIN; PROTEIN MOTIF; REPEATED DRUG DOSE; SPLEEN CELL; T LYMPHOCYTE; TAUOPATHY; VACCINATION; ANIMAL; BLOOD; CELL PROLIFERATION; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; ENCEPHALITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MUTATION; PATHOLOGY; PROCEDURES; TAUOPATHIES; TRANSGENIC MOUSE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES; CELL PROLIFERATION; CYTOKINES; DISEASE MODELS, ANIMAL; ENCEPHALITIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EPITOPES; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; MICE; MICE, TRANSGENIC; MUTATION; SAPONINS; T-LYMPHOCYTES; TAU PROTEINS; TAUOPATHIES; VACCINATION;

EID: 84908130851     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-014-0152-0     Document Type: Article

References (54)

1. Bi M, Ittner A, Ke YD, Gotz J, Ittner LM. Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One 2011, 6:e26860. 10.1371/journal.pone.0026860, 22174735.
2. Armstrong RA, Lantos PL, Cairns NJ. Progressive supranuclear palsy (PSP): a quantitative study of the pathological changes in cortical and subcortical regions of eight cases. J Neural Transm 2007, 114:1569-1577. 10.1007/s00702-007-0796-3, 17680229.
3. Riedl L, Mackenzie IR, Forstl H, Kurz A, Diehl-Schmid J. Frontotemporal lobar degeneration: current perspectives. Neuropsychiatr Dis Treat 2014, 10:297-310. 24600223.
4. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, Dickson DW, Davies P, Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 2000, 25:402-405. 10.1038/78078, 10932182.
5. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005, 309:476-481. 10.1126/science.1113694, 16020737.
6. Denk F, Wade-Martins R. Knock-out and transgenic mouse models of tauopathies. Neurobiol Aging 2009, 30:1-13. 10.1016/j.neurobiolaging.2007.05.010, 17590238.
7. Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, Duff K, Davies P. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 2003, 86:582-590. 10.1046/j.1471-4159.2003.01879.x, 12859672.
8. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 2011, 118:658-667. 10.1111/j.1471-4159.2011.07337.x, 21644996.
9. Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 2010, 30:16559-16566. 10.1523/JNEUROSCI.4363-10.2010, 21147995.
10. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 2007, 27:9115-9129. 10.1523/JNEUROSCI.2361-07.2007, 17715348.
11. D'Abramo C, Acker CM, Jimenez HT, Davies P. Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. PLoS One 2013, 8:e62402. 10.1371/journal.pone.0062402, 23638068.
12. Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K. Trans-synaptic spread of tau pathology in vivo. PLoS One 2012, 7:e31302. 10.1371/journal.pone.0031302, 22312444.
13. Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 2009, 284:12845-12852. 10.1074/jbc.M808759200, 19282288.
14. de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 2012, 73:685-697. 10.1016/j.neuron.2011.11.033, 22365544.
15. Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Lasagna-Reeves CA, Gerson JE, Singh G, Estes DM, Barrett AD, Dineley KT, Jackson GR, Kayed R. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci 2014, 34:4260-4272. 10.1523/JNEUROSCI.3192-13.2014, 24647946.
16. Castillo-Carranza DL, Gerson JE, Sengupta U, Guerrero-Munoz MJ, Lasagna-Reeves CA, Kayed R. Specific targeting of Tau oligomers in htau mice prevents cognitive impairment and Tau toxicity following injection with brain-derived Tau oligomeric seeds. J Alzheimers Dis 2014, 40:S97-S111. 24603946.
17. Kayed R. Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease. Hum Vaccin 2010, 6:931-935. 10.4161/hv.6.11.12689, 20980799.
18. Boutajangout A, Sigurdsson EM, Krishnamurthy PK. Tau as a therapeutic target for Alzheimer's disease. Curr Alzheimer Res 2011, 8:666-677. 10.2174/156720511796717195, 21679154.
19. Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, Buckner N, Hanmer J, Davies P, O'Neill MJ, Hutton ML, Citron M. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem 2011, 286:34457-34467. 10.1074/jbc.M111.229633, 21841002.
20. Gu J, Congdon EE, Sigurdsson EM. Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology. J Biol Chem 2013, 288:33081-33095. 10.1074/jbc.M113.494922, 24089520.
21. Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, Zommer N, Sergeant N, Schraen-Maschke S, Blum D, Buee L. Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res 2012, 9:397-405. 10.2174/156720512800492503, 22272619.
22. Selenica ML, Brownlow M, Jimenez JP, Lee DC, Pena G, Dickey CA, Gordon MN, Morgan D. Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy. Neurodegener Dis 2013, 11:165-181. 10.1159/000337230, 22796753.
23. Davtyan H, Mkrtichyan M, Movsesyan N, Petrushina I, Mamikonyan G, Cribbs DH, Agadjanyan MG, Ghochikyan A. DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice. Gene Ther 2010, 17:261-271. 10.1038/gt.2009.140, 19865176.
24. Petrushina I, Ghochikyan A, Mktrichyan M, Mamikonyan G, Movsesyan N, Davtyan H, Patel A, Head E, Cribbs DH, Agadjanyan MG. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. J Neurosci 2007, 27:12721-12731. 10.1523/JNEUROSCI.3201-07.2007, 18003852.
25. Selenica ML, Alvarez JA, Nash KR, Lee DC, Cao C, Lin X, Reid P, Mouton PR, Morgan D, Gordon MN. Diverse activation of microglia by chemokine (C-C motif) ligand 2 overexpression in brain. J Neuroinflammation 2013, 10:86. 10.1186/1742-2094-10-86, 23866683.
26. Lee DC, Rizer J, Selenica ML, Reid P, Kraft C, Johnson A, Blair L, Gordon MN, Dickey CA, Morgan D. LPS-induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J Neuroinflammation 2010, 7:56. 10.1186/1742-2094-7-56, 20846376.
27. Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW, Connor K, Melachrino J, O'Callaghan JP, Morgan D. Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1 + APP mouse. Exp Neurol 2002, 173:183-195. 10.1006/exnr.2001.7754, 11822882.
28. Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 2010, 224:472-485. 10.1016/j.expneurol.2010.05.010, 20546729.
29. Dickey C, Kraft C, Jinwal U, Koren J, Johnson A, Anderson L, Lebson L, Lee D, Dickson D, de Silva R, Binder LI, Morgan D, Lewis J. Aging analysis reveals slowed tau turnover and enhanced stress response in a mouse model of tauopathy. Am J Pathol 2009, 174:228-238. 10.2353/ajpath.2009.080764, 19074615.
30. Thompson AD, Scaglione KM, Prensner J, Gillies AT, Chinnaiyan A, Paulson HL, Jinwal UK, Dickey CA, Gestwicki JE. Analysis of the tau-associated proteome reveals that exchange of Hsp70 for Hsp90 is involved in tau degradation. ACS Chem Biol 2012, 7:1677-1686. 10.1021/cb3002599, 22769591.
31. Lee DC, Ruiz CR, Lebson L, Selenica ML, Rizer J, Hunt JB, Rojiani R, Reid P, Kammath S, Nash K, Dickey CA, Gordon MN, Morgan D. Aging enhances classical activation but mitigates alternative activation in the central nervous system. Neurobiol Aging 2013, 34:1610-1620. 10.1016/j.neurobiolaging.2012.12.014, 23481567.
32. Colton C, Wilcock DM. Assessing activation states in microglia. CNS Neurol Disord Drug Targets 2010, 9:174-191. 10.2174/187152710791012053, 20205642.
33. Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 2013, 80:402-414. 10.1016/j.neuron.2013.07.046, 24075978.
34. Prinz M, Mildner A. Microglia in the CNS: immigrants from another world. Glia 2011, 59:177-187. 10.1002/glia.21104, 21125659.
35. Town T, Laouar Y, Pittenger C, Mori T, Szekely CA, Tan J, Duman RS, Flavell RA. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med 2008, 14:681-687. 18516051.
36. Gate D, Rezai-Zadeh K, Jodry D, Rentsendorj A, Town T. Macrophages in Alzheimer's disease: the blood-borne identity. J Neural Transm 2010, 117:961-970. 10.1007/s00702-010-0422-7, 20517700.
37. Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, Miller R, Berry RW, Binder LI, Cryns VL. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci U S A 2003, 100:10032-10037. 10.1073/pnas.1630428100, 12888622.
38. Ghoshal N, Garcia-Sierra F, Wuu J, Leurgans S, Bennett DA, Berry RW, Binder LI. Tau conformational changes correspond to impairments of episodic memory in mild cognitive impairment and Alzheimer's disease. Exp Neurol 2002, 177:475-493. 10.1006/exnr.2002.8014, 12429193.
39. Horowitz PM, Patterson KR, Guillozet-Bongaarts AL, Reynolds MR, Carroll CA, Weintraub ST, Bennett DA, Cryns VL, Berry RW, Binder LI. Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer's disease. J Neurosci 2004, 24:7895-7902. 10.1523/JNEUROSCI.1988-04.2004, 15356202.
40. Yin H, Kuret J. C-terminal truncation modulates both nucleation and extension phases of tau fibrillization. FEBS Lett 2006, 580:211-215. 10.1016/j.febslet.2005.11.077, 16364303.
41. Basurto-Islas G, Luna-Munoz J, Guillozet-Bongaarts AL, Binder LI, Mena R, Garcia-Sierra F. Accumulation of aspartic acid421- and glutamic acid391-cleaved tau in neurofibrillary tangles correlates with progression in Alzheimer disease. J Neuropathol Exp Neurol 2008, 67:470-483. 10.1097/NEN.0b013e31817275c7, 18431250.
42. Abraha A, Ghoshal N, Gamblin TC, Cryns V, Berry RW, Kuret J, Binder LI. C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease. J Cell Sci 2000, 113:3737-3745. 11034902.
43. Leroy K, Bretteville A, Schindowski K, Gilissen E, Authelet M, De Decker R, Yilmaz Z, Buee L, Brion JP. Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice. Am J Pathol 2007, 171:976-992. 10.2353/ajpath.2007.070345, 17690183.
44. de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spires-Jones TL, Hyman BT. Caspase activation precedes and leads to tangles. Nature 2010, 464:1201-1204. 10.1038/nature08890, 20357768.
45. Vana L, Kanaan NM, Ugwu IC, Wuu J, Mufson EJ, Binder LI. Progression of tau pathology in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease. Am J Pathol 2011, 179:2533-2550. 10.1016/j.ajpath.2011.07.044, 21945902.
46. Schneider A, Biernat J, von Bergen M, Mandelkow E, Mandelkow EM. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 1999, 38:3549-3558. 10.1021/bi981874p, 10090741.
47. Friedhoff P, von Bergen M, Mandelkow EM, Mandelkow E. Structure of tau protein and assembly into paired helical filaments. Biochim Biophys Acta 2000, 1502:122-132. 10.1016/S0925-4439(00)00038-7, 10899437.
48. Bulic B, Pickhardt M, Mandelkow EM, Mandelkow E. Tau protein and tau aggregation inhibitors. Neuropharmacology 2010, 59:276-289. 10.1016/j.neuropharm.2010.01.016, 20149808.
49. von Bergen M, Barghorn S, Muller SA, Pickhardt M, Biernat J, Mandelkow EM, Davies P, Aebi U, Mandelkow E. The core of tau-paired helical filaments studied by scanning transmission electron microscopy and limited proteolysis. Biochemistry 2006, 45:6446-6457. 10.1021/bi052530j.
50. Krishnamurthy PK, Deng Y, Sigurdsson EM. Mechanistic studies of antibody-mediated clearance of Tau aggregates using an ex vivo brain slice model. Front Psychiatry 2011, 2:59. 10.3389/fpsyt.2011.00059, 22025915.
51. Sigurdsson EM. Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. Curr Alzheimer Res 2009, 6:446-450. 10.2174/156720509789207930, 19874269.
52. Lim F, Hernandez F, Lucas JJ, Gomez-Ramos P, Moran MA, Avila J. FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain. Mol Cell Neurosci 2001, 18:702-714. 10.1006/mcne.2001.1051, 11749044.
53. Yamada K, Holth JK, Liao F, Stewart FR, Mahan TE, Jiang H, Cirrito JR, Patel TK, Hochgrafe K, Mandelkow EM, Holtzman DM. Neuronal activity regulates extracellular tau in vivo. J Exp Med 2014, 211:387-393. 10.1084/jem.20131685, 24534188.
54. Clavaguera F, Grueninger F, Tolnay M. Intercellular transfer of tau aggregates and spreading of tau pathology: implications for therapeutic strategies. Neuropharmacology 2014, 76 Pt A:9-15. 10.1016/j.neuropharm.2013.08.037, 24050961.